Gilenya for Multiple SclerosisGilenya, a medication approved for the treatment of relapsing forms of Multiple Sclerosis (MS), has gained recognition as a promising therapeutic option for patients.
A breakthrough for Alzheimer’s disease: a new drug improves memory and cognitionAlzheimer’s disease is one of the most devastating and common neurodegenerative disorders in the world.
A new way to treat multiple sclerosis by re-establishing immune toleranceMultiple sclerosis (MS) is a disease that affects the nervous system, causing inflammation and damage to the protective layer of nerve fibers.
How deep learning can help predict disability progression in multiple sclerosisMultiple sclerosis (MS) is a chronic neurological disease that affects millions of people worldwide.
The latest research on multiple sclerosis: insights from Nature journalsNature journals are among the leading sources of scientific information on MS, covering various aspects of the disease from basic immunology to clinical trials.
The latest research on multiple sclerosis: insights from The Lancet journalsThe Lancet journals are among the leading sources of scientific information on MS, covering various aspects of the disease from basic immunology to clinical trials.
The link between early depression and disability in multiple sclerosisA new study published in Scientific Reports1 examines the relationship between early depressive symptoms and disability accrual in people with multiple sclerosis (MS).
